RTI Surgical® Announces a Centers for Medicare and Medicaid Services’ Physician Payment Increase for Minimally Invasive SI...
November 05 2019 - 7:05AM
RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical
implant company, today announced an increase to the Centers for
Medicare and Medicaid Services’ (CMS) Medicare Physician Fee
Schedule for CPT® Code 27279, Arthrodesis Sacroiliac Joint,
used to report minimally invasive sacroiliac (SI) joint fusion
procedures. These procedures can be performed using RTI’s
SImmetry® Sacroiliac Joint Fusion System, which is a minimally
invasive surgical solution that uses proprietary decortication
technology, bone grafting and threaded fixation to facilitate bone
fusion, providing an opportunity for long-term pain relief.
As of January 1, 2020, CMS will increase the Relative Value
Units (RVUs) associated with CPT® Code 27279 from 9.03 to
12.13. As part of this increase, Medicare national average payments
will increase from $720 to $914.52, which is approximately 27%
greater than today. CMS updated CPT Code 27279 to increase the
physician work value after a comprehensive review determined an
undervaluation of the procedure. Data and commentary from surgeons
and other interested parties across the U.S. showed the RVUs
associated for minimally invasive SI joint fusion procedures
understated the physician time and complexity required.
“RTI is pleased with the recent CMS decision to increase the
physician work value to perform minimally invasive SI joint fusion
procedures, including those done with the SImmetry System,” said
Camille Farhat, President and CEO, RTI Surgical. “Interim results
of the EVoluSIon study for the SImmetry System continue to
demonstrate promising results in evidence of fusion, reduction in
pain from baseline and reduced opioid use.”
RTI has completed enrollment for the EVoluSIon Clinical Trial
evaluating the impact of the SImmetry System on SI joint pain
reduction on 250 patients. The company released interim clinical
outcomes in a whitepaper at NASS 2019 in Chicago on 150 patients
who have reached their 6-month follow-up showing:
- Mean Visual Analog Scale (VAS) SI joint pain decreasing from
77.2 at baseline to 33.3, a statistically significant reduction in
pain of 56%.
- Mean Oswestry Disability Index (ODI) scores improving from 54.1
at baseline to 32.8, a statistically significant and clinically
meaningful improvement in disability related to SI joint pain.
- A statistically significant decline in opioid use with 62% of
patients reporting taking opioids prior to surgery, and 34%
reporting taking opioids post-surgery – a decrease of 45%.
- A decrease in the use of non-opioid pain medications such as
NSAIDs, analgesics and steroids.
About RTI Surgical Holdings, Inc.
RTI Surgical is a leading global surgical implant company
providing surgeons with safe biologic, metal and synthetic
implants. Committed to delivering a higher standard, RTI’s implants
are used in sports medicine, general surgery, spine, orthopedic and
trauma procedures and are distributed in nearly 50 countries. RTI
has four manufacturing facilities throughout the U.S. and Europe.
RTI is accredited in the U.S. by the American Association of Tissue
Banks and is a member of AdvaMed. For more information, please
visit www.rtix.com. Connect with us
on LinkedIn and Twitter. Clinical cases are unique
and individual results may vary. Regulatory approvals vary by
country. Therefore, we kindly ask you to contact your RTI Surgical
regional leader regarding availability of specific products,
implants and/or instrumentation in your region.
Forward-Looking Statements
Portions of this document may constitute “forward-looking
statements” as defined by federal law. Although the company
believes any such statements are based on reasonable assumptions,
there is no assurance that actual outcomes will not be materially
different. Any such statements are made in reliance on the “safe
harbor” protections provided under the Private Securities Reform
Act of 1995. Additional information about issues that could lead to
material changes in performance is contained in the company’s
annual and quarterly reports filed with the Securities and Exchange
Commission.
Steven Cohen Media Contact scohen@rtix.com +1
847 648 0861
Molly Poarch Investor Contact mpoarch@rtix.com
+1 224 287 2661
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
RTI Surgical (NASDAQ:RTIX)
Historical Stock Chart
From Apr 2023 to Apr 2024